Novel erythropoiesis stimulating protein.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Seminars in Nephrology

• Publication date

  2000-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 10928340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

  1999cited by this paper
• Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.

  1993cited by this paper
• Biological roles of oligosaccharides: all of the theories are correct

  1993cited by this paper
• Clinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin)

  1991cited by this paper
• USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients.

  1990cited by this paper
• Clinical Pharmacology of Recombinant Human Erythropoietin (r‐HuEPO)

  1990cited by this paper
• The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin.

  1989cited by this paper
• Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients.

  1989cited by this paper
• Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

  1989cited by this paper
• Comparative Pharmacokinetics of Recombinant Erythropoietin Administered by the Intravenous, Subcutaneous, and Intraperitoneal Routes in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients

  1989cited by this paper
• Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.

  1989cited by this paper
• Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

  1987cited by this paper
• Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

  1986cited by this paper
• Erythropoietin levels in uremic nephric and anephric patients.

  1979cited by this paper

• Low-Dose Erythropoietin Amplifies Beneficial Effects of Angiotensin II Blockade on Glomerulosclerosis.

  2023cites this paper
• Erythropoietin

  2021cites this paper
• Role of erythropoietin and its receptor in the development of endometriosis in rats

  2018cites this paper
• Development and Characterization of Darbepoetin

  2017cites this paper
• Advanced Immunoinformatics Approaches for Precision Medicine

  2016cites this paper
• Erythropoietin and thrombopoietin mimetics: Natural alternatives to erythrocyte and platelet disorders.

  2016cites this paper
• Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy

  2015cites this paper
• Subcutaneous versus intravenous erythropoietin for long‐term dialysis patients

  2015cites this paper
• membrane transport protein expressions in humans Effects of darbepoetin injections on erythrocyte

  2015cites this paper
• Darbepoetin for the anaemia of chronic kidney disease.

  2014cites this paper
• The Cancer Burden and Patterns of Erythropoiesis-stimulating Agent Use Among End-stage Renal Disease Patients on Hemodialysis

  2014cites this paper
• Darbepoietin-alfa has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironment

  2013cites this paper
• Darbepoietin-a has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironment

  2012cites this paper
• Darbepoetin Alfa

  2012cites this paper
• Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments

  2012cites this paper
• Clinical and economic impact of epoetins in cancer care

  2012cites this paper
• Erythropoiesis-stimulating agents for the management of anemia of chronic kidney disease: past advancements and current innovations.

  2012cites this paper
• Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease

  2012cites this paper
• Extended dosing of darbepoetin alfa in peritoneal dialysis patients

  2011cites this paper
• Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study

  2011influential citation
• Hématologie et hémostase

  2011cites this paper
• Biosimilares: balance de eficacia, seguridad y coste

  2010cites this paper
• Incorporating novel agents in the treatment of myelodysplastic syndromes.

  2010cites this paper
• Cracking the Glycocode: Recent Developments in Glycomics

  2010cites this paper
• The Influence of Formula Concentration on the Absorption of Darbepoetin Alfa after Subcutaneous Administration

  2010cites this paper
• Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences

  2010cites this paper
• Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.

  2010cites this paper
• [Biosimilars: assessment of efficacy, safety and cost].

  2010cites this paper
• Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration

  2009cites this paper
• Pretreatment with Darbepoetin Attenuates Renal Injury in a Rat Model of Cisplatin-Induced Nephrotoxicity

  2009cites this paper
• Reducing the immunogenicity of protein therapeutics.

  2009cites this paper
• Efficacy of recombinant erythropoietins: is there unity of international units?

  2009cites this paper
• Erythropoietin's impact on endurance performance under normoxic condition and upon acclimatization to moderate altitude

  2009cites this paper
• Erythropoiesis stimulating agents and techniques: a challenge for doping analysts.

  2009cites this paper
• Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.

  2008cites this paper
• Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations

  2008cites this paper
• Hematology and Hemostasis

  2008cites this paper
• Treatment and costs associated with anemic chronic kidney disease patients

  2008cites this paper
• Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.

  2008cites this paper
• Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open‐label, Australian study

  2007cites this paper
• Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model

  2007influential citation
• Recombinant EPO production--points the nephrologist should know.

  2007cites this paper
• Population pharmacokinetics of darbepoetin alfa in healthy subjects.

  2007cites this paper
• Erythropoietin after a century of research: younger than ever

  2007cites this paper
• Perspectives in the treatment of renal anaemia new concepts and new drugs.

  2007influential citation
• The role of erythropoietin in central and peripheral nerve injury.

  2007cites this paper
• Cancer-related anemia: clinical review and management update.

  2007cites this paper
• Biochemistry, Physiology, and Complications of Blood Doping: Facts and Speculation

  2006cites this paper
• Effects of darbepoetin injections on erythrocyte membrane transport protein expressions in humans.

  2006influential citation
• Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis*

  2006cites this paper
• The Absorption of Darbepoetin Alfa Occurs Predominantly via the Lymphatics Following Subcutaneous Administration to Sheep

  2006cites this paper
• An Extended Terminal Half-Life for Darbepoetin Alfa

  2006cites this paper
• Anemia in the elderly-clinical findings and impact on health.

  2006cites this paper
• Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure.

  2006cites this paper
• Determination of KRN321 in Rat Serum by ELISA and Correlation Between ELISA and in vitro Bioassay

  2006cites this paper
• DEFICIENCIA DE HIERRO.

  2006cites this paper
• Érythropoïèse et bronchopneumopathie chronique obstructive

  2006cites this paper
• Haemopoietic growth factors in the treatment of myelodysplastic syndrome

  2006influential citation
• [Darbepoetin in the treatment of the renal anaemia in the patient undergoing peritoneal dialysis previously treated with epoetin alfa].

  2005cites this paper
• Darbepoetin alfa (Aranesp™) in children with chronic renal failure

  2005cites this paper
• Efficient Monthly Subcutaneous Administration of Darbepoetin in Stable CAPD Patients

  2005cites this paper
• Darbepoetin alfa (Aranesp TM )i nchildren with chronic renal failure

  2005cites this paper
• Anaemia in cancer patients: pathophysiology, incidence and treatment

  2005cites this paper
• Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia: A Pharmacokinetic and Pharmacodynamic Investigation

  2005cites this paper
• Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.

  2005cites this paper
• [Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha].

  2004cites this paper
• Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis

  2004cites this paper
• Over 5 years of darbepoetin alfa: two case histories

  2004cites this paper
• Current and future use of hematopoietic growth factors in cancer medicine

  2004cites this paper
• Cancer-related anemia.

  2004cites this paper
• Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

  2004cites this paper
• High-level in vivo gene marking after gene-modified autologous hematopoietic stem cell transplantation without marrow conditioning in nonhuman primates.

  2004cites this paper
• Erythropoietin and the developing brain

  2004cites this paper
• The Safety of Hematopoietic Growth Factors

  2004cites this paper
• [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].

  2004cites this paper
• Hematopoietic Growth Factors

  2004cites this paper
• Differentiating Factors Between Erythropoiesis-Stimulating Agents

  2004cites this paper
• Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells.

  2004cites this paper
• [Erythropoietin administration to preterm infants: comparison between subcutaneous and intravenous route].

  2004cites this paper
• In vivo expansion of gene‐modified hematopoietic cells by a novel selective amplifier gene utilizing the erythropoietin receptor as a molecular switch

  2004cites this paper
• The cardiovascular effects of erythropoietin.

  2003influential citation
• Treatment of Anemia with Darbepoetin Alfa Administered de novo Once Every Other Week in Chronic Kidney Disease

  2003cites this paper
• Red-Cell Aplasia Due to Antibodies against Human Recombinant Erythropoietin (rHuEPO) in a Peritoneal Dialysis Patient Treated with rHuEPO

  2003cites this paper
• Erythropoietin: Physiology and Pharmacology Update 2

  2003cites this paper
• Kinetics of haematopoietic recovery after dose‐intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha

  2003cites this paper
• A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.

  2003cites this paper
• Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone.

  2003cites this paper
• Anaemia in heart failure: its diagnosis and management

  2003cites this paper
• The development of supportive-care agents for patients with cancer.

  2003cites this paper
• Effects of cancer-related anemia on clinical and quality-of-life outcomes.

  2002cites this paper
• Darbepoetin Alfa: A Novel Erythropoiesis-Stimulating Protein

  2002cites this paper
• Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.

  2002cites this paper
• Further concerns about the medical risks of blood doping.

  2002cites this paper
• Darbepoetin alfa: potential role in managing anemia in cancer patients

  2002cites this paper
• Darbepoetin Alfa (Aranesp)

  2002cites this paper
• Overview of Cancer‐Related Anemia: Focus on the Potential Role of Darbepoetin alfa

  2002influential citation
• Darbepoetin alfa: a new therapeutic agent for renal anemia.

  2002cites this paper
• Darbepoetin alfa, a New Therapy for the Management of Anemia of Chronic Kidney Disease

  2002cites this paper
• The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP

  2002cites this paper
• Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.

  2002cites this paper